Key result
Coronary microvascular dysfunction contributes to cardiac dysfunction and disease progression across various human cardiomyopathies, though current therapies lack specificity.
This review highlights the critical role of coronary microcirculatory dysfunction in the pathophysiology and progression of various human cardiomyopathies.
CMD warrants no therapy change in cardiomyopathies; leaves open targeted microvascular interventions for prospective trials.
Cardiomyopathies are a heterogeneous group of diseases of the myocardium. The term cardiomyopathy involves a wide range of pathogenic mechanisms that affect the structural and functional states of cardiomyocytes, extravascular tissues, and coronary vasculature, including both epicardial coronary arteries and the microcirculation. In the developed phase, cardiomyopathies present with various clinical symptoms: dyspnea, chest pain, palpitations, swelling of the extremities, arrhythmias, and sudden cardiac death. Due to the heterogeneity of cardiomyopathic patterns and symptoms, their diagnosis and therapies are great challenges. Despite extensive research, the relation between the structural and functional abnormalities of the myocardium and the coronary circulation are still not well understood in the various forms of cardiomyopathy. The main pathological characteristics of cardiomyopathies and the coronary microcirculation develop in a progressive manner due to (1) genetic-immunologic-systemic factors; (2) comorbidities with endothelial, myogenic, metabolic, and inflammatory changes; (3) aging-induced arteriosclerosis; and (4) myocardial fibrosis. The aim of this review is to summarize the most important common pathological features and/or adaptations of the coronary microcirculation in various types of cardiomyopathies and to integrate the present understanding of the underlying pathophysiological mechanisms responsible for the development of various types of cardiomyopathies. Although microvascular dysfunction is present and contributes to cardiac dysfunction and the potential outcome of disease, the current therapeutic approaches are not specific for the given types of cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Selthofer-Relatić et al. (2017) conducted a review in Cardiomyopathies. Coronary microvascular dysfunction contributes to cardiac dysfunction and disease progression across various human cardiomyopathies, though current therapies lack specificity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: